Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.
Sarepta Therapeutics, Inc. develops and commercializes precision genetic medicines for rare diseases, with a central focus on Duchenne muscular dystrophy and other neuromuscular conditions. Company news commonly covers product revenue and commercialization trends for ELEVIDYS and PMO therapies, including AMONDYS 45, VYONDYS 53 and EXONDYS 51.
Updates also address FDA interactions for Duchenne therapies, clinical and biomarker data from the siRNA pipeline, and programs such as SRP-1001 for FSHD1 and SRP-1003 for DM1. Other recurring announcements include quarterly financial results, Nasdaq inducement equity grants, and patient-community initiatives tied to Duchenne muscular dystrophy.
Sarepta Therapeutics (NASDAQ:SRPT) has announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 1:30 p.m. E.T. in San Francisco, California. A Q&A session will follow at 1:50 p.m. E.T. The presentation will be available via live webcast on Sarepta's investor relations website and archived for 90 days thereafter. Sarepta focuses on precision genetic medicine for rare diseases, with over 40 programs in development, particularly in Duchenne muscular dystrophy and limb-girdle muscular dystrophies. For more details, visit their website.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced the granting of equity awards to 42 newly hired employees as of November 30, 2022. The awards, approved by the Compensation Committee under the 2014 Employment Commencement Incentive Plan, include options to purchase 55,000 shares and 28,500 restricted stock units (RSUs). The options have an exercise price of $122.81 per share, equal to the stock's closing price on the grant date. Both the options and RSUs will vest over four years, contingent upon continued employment.
Sarepta Therapeutics has announced that the FDA has accepted its Biologics License Application (BLA) for SRP-9001 (delandistrogene moxeparvovec) aimed at treating Duchenne muscular dystrophy (DMD). The FDA has granted priority review, with a regulatory action date set for May 29, 2023. The drug, a one-time gene therapy, delivers a functional form of dystrophin to muscle tissue. Positive clinical trial results from over 80 patients and an ongoing global study (EMBARK) further support its potential. The outcome could significantly impact the treatment landscape for DMD.
Sarepta Therapeutics (NASDAQ:SRPT) announced that its senior management will participate in a fireside chat during the 5th Annual Evercore ISI HealthCONx Conference on December 1, 2022, at 2:15 p.m. E.T. The event will be held virtually and available for live streaming on the investor relations section of Sarepta's website. The presentation will remain archived for 90 days post-event. Sarepta is dedicated to developing precision genetic medicine for rare diseases, with over 40 programs in development.
Sarepta Therapeutics (NASDAQ:SRPT) reported Q3 2022 revenues of $230.3 million, with net product revenues up 24% year-over-year at $207.8 million. The company submitted a Biologics License Application for its gene therapy SRP-9001 targeting Duchenne muscular dystrophy, based on promising clinical results. Additionally, Sarepta raised $1.2 billion to support the therapy's launch. However, the company posted a net loss of $257.7 million for the quarter, an increase from a loss of $48.1 million in Q3 2021.
Sarepta Therapeutics (NASDAQ:SRPT) granted equity awards to 34 new employees on October 31, 2022. The awards include options for 31,125 shares and 16,075 restricted stock units (RSUs). The options have an exercise price of $114.02 per share, matching the closing price on the grant date. Options will vest over four years, with one-fourth vesting after one year and the rest vesting monthly. RSUs will vest annually over the same timeframe. This initiative was approved under Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.
Sarepta Therapeutics (NASDAQ: SRPT) will announce its third quarter 2022 financial results on November 2, 2022, after market close. A conference call will follow at 4:30 p.m. E.T. to discuss the results. Sarepta, a leader in precision genetic medicine, focuses on rare diseases, particularly Duchenne muscular dystrophy and limb-girdle muscular dystrophies, with over 40 programs in development. The event will be available via live webcast and archived on the company's investor relations website for one year.
Sarepta Therapeutics (NASDAQ:SRPT) will present new data from its genetic medicine portfolio at the 27th International Hybrid Annual Congress of the World Muscle Society 2022 from October 11-15 in Halifax, Canada. Key presentations include real-world evidence on eteplirsen for Duchenne and preclinical data for SRP-9001, a gene therapy targeting Duchenne muscular dystrophy. The company's commitment to advancing treatments is emphasized by its extensive research and development efforts.
Sarepta Therapeutics (NASDAQ:SRPT) granted equity awards on September 30, 2022, to 43 new employees as part of its 2014 Employment Commencement Incentive Plan. The total awards included options to purchase 53,575 shares and 27,525 restricted stock units (RSUs). The options have an exercise price of $110.54 per share, matching the closing stock price on the Grant Date. Vesting for options occurs over four years, while RSUs also vest over four years, contingent on continued employment.
Sarepta Therapeutics (NASDAQ:SRPT) announced the submission of a Biologics License Application (BLA) to the FDA for accelerated approval of SRP-9001, a gene therapy for Duchenne muscular dystrophy. The application is based on positive clinical trial results showing effective dystrophin protein expression and a consistent safety profile. The fully-enrolled EMBARK study will serve as the post-marketing confirmatory trial. SRP-9001 holds Fast Track and Rare Pediatric Disease designations, enhancing its development prospects.